Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $401.2 million.

  • Madrigal Pharmaceuticals' Operating Expenses rose 12481.24% to $401.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 6773.55%. This contributed to the annual value of $678.0 million for FY2024, which is 7819.06% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Operating Expenses stood at $401.2 million for Q3 2025, which was up 12481.24% from $260.0 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Operating Expenses high stood at $401.2 million for Q3 2025, and its period low was $53.0 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $86.4 million (2023), whereas its average is $130.1 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Operating Expenses surged by 744.05% in 2021 and then skyrocketed by 12481.24% in 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Operating Expenses (Quarter) stood at $64.6 million in 2021, then soared by 32.04% to $85.3 million in 2022, then skyrocketed by 37.37% to $117.2 million in 2023, then skyrocketed by 45.35% to $170.3 million in 2024, then surged by 135.59% to $401.2 million in 2025.
  • Its Operating Expenses stands at $401.2 million for Q3 2025, versus $260.0 million for Q2 2025 and $216.6 million for Q1 2025.